View Older Stories View More Recent Stories
-
Is the U.S. drug pricing deal good for Pfizer?
-
TD Cowen on Pfizer (PFE): 'MFN Agreement an Important Positive'
-
Pfizer (PFE) call put ratio 7.5 calls to 1 put with a focus on 10K contracts of March 29 calls as share price up 6.3%
-
Popular stocks with increasing volume: PFE CRWV SOFI INTC HOOD PLTR SNAP AMD NIO ORCL SMCI NKE
-
Trump admin official: we hope to have Trump Rx.gov live early in 2026
-
Pfizer reaches agreement with U.S. government to lower drug prices
-
BMO on Pfizer (PFE) and Trump Deal: 'Announcement serves as a positive to the BioPharma sector'
-
Fact Sheet: President Donald J. Trump Announces First Deal to Bring Most-Favored-Nation Pricing to American Patients
-
Pfizer Gets Three-year Grace Period From Trump Pharma Tariffs
-
Pfizer CEO Bourla comments on drug deal with Trump admin
-
Trump on deal with Pfizer: we're going to be paying the lowest price, other drugmakers will commit in coming weeks
-
Trump says we’ll be reducing prices (of drugs) by a 100% and in some cases more
-
White House to Announce 'TrumpRx' Drug-Buying Website, and Deal With Pfizer -- WSJ
-
Trump to announce drug-pricing deal with Pfizer -Wapo
-
Bernstein on AmericasMedicines.com: 'The Noise Starts, But Not (Yet) from Trump'
-
Cantor Fitzgerald Reiterates Neutral Rating on Pfizer (PFE)
-
Rfk Jr. Weighs Expansion Of Vaccine Injury Program: Adviser - Bloomberg
-
Pfizer presents cancer data at ESMO 2025 with over 45 abstracts
-
BMO Capital on Pfizer (PFE): 'Metsera Acquisition Moves PFE Back in the Obesity Spotlight'
-
BMO Capital on Pfizer (PFE): 'Metsera Acquisition Moves PFE Back in the Obesity Spotlight'
-
Bernstein on Pfizer (PFE): 'PFE - Back In Business?'
-
Goldman on Pfizer (PFE) Post Metsera (MTSR) Deal: 'previously emphasized the importance of growing its footprint in internal medicines and primary care'
-
BTIG on Pfizer (PFE) deal for Metsera (MTSR): 'representative of large pharma's strong interest in the obesity and metabolic disease platforms'
-
Wolfe Research Comments on Path Forward for Pfizer (PFE) and Metsera (MTSR)
-
Pfizer (PFE) Nears Potential $7.3 bln Takeover Of Metsera- FT
-
CDC Panel Votes Against Requiring Prescriptions For Covid Shots - Bloomberg
-
CDC Panel Votes To End Universal Recommendation For Covid Shots - Bloomberg
-
Raymond James: 'LinkedIn posts from executives at AbbVie indicate that the company has selected Salesforce for its future CRM'
-
Arvinas and Pfizer to out-license vepdegestrant commercialization rights
-
Kennedy To Change Childhood Vaccine Schedule In Sept: Monarez - Bloomberg
-
Pfizer reaffirms COVID-19 vaccine safety and efficacy data
-
Pfizer (PFE) call put ratio 1.4 calls to 1 put as share price down 3.2%
-
Pfizer, Moderna, BioNTech trade lower amid report of vaccine link to child deaths
-
US officials plan to link 25 child deaths to covid shots - WaPo
-
Raymond James Comments on FDA and HHS Reforms for DTC Pharma Advertising
-
Pfizer and BioNTech report positive data for LP.8.1 COVID vaccine
-
Rfk Jr. Moves To Add More Hand-picked Vaccine Advisory Members - Bloomberg
-
Olema Pharmaceuticals (OLMA) latest collaboration could create future 'bidding war' - Oppenheimer
-
Pfizer reaffirms commitment to COVID-19 vaccine transparency
-
Olema Oncology partners with Pfizer for breast cancer drug trial
-
White House Taps Top RFK Jr. Deputy As Acting CDC Director - Washington Post
-
CDC Director Monarez Is Being Ousted - WAPO
-
FDA Authorizes Covid Vaccines For Those At Higher Risk - Kennedy
-
Pfizer (PFE) says Phase 3 Thrive-131 study did not meet its primary endpoint
-
Pfizer (PFE) experimental sickle cell drug fails Phase 3 trial - CNBC
-
Starboard Releases 13F, Shows Two New Stakes
-
U.S. Government's Announcement On Pharma Sector Probe And Tariffs Unlikely For A Few Weeks, Sources Say - Reuters
-
Cantor Fitzgerald Reiterates Neutral Rating on Pfizer (PFE)
-
Pfizer, Astellas report positive trial results for bladder cancer combo
-
FDA accepts Arvinas drug application for advanced breast cancer treatment
